Anti-Mouse BTLA/CD272 Antibody (6A6)
Based on 1 Customer Validation
Anti-Mouse BTLA/CD272 Antibody (6A6) is an Armenian hamster-derived anti-mouse BTLA/CD272 IgG κ type antibody inhibitor. Anti-Mouse BTLA/CD272 Antibody (6A6) can be used for the researches of cancer and immunology, such as graft versus host disease (GVHD) and WF-3/Luc tumor.
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Armenian hamster IgG
Mouse
BTLA/CD272
Anti-Mouse BTLA/CD272 Antibody (6A6) (20 μg/mL, 1 h) significantly decreases percentages of BTLA+ CD19high B lymphocytes in IL-6-or IL-10-treated B lymphocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse BTLA/CD272 Antibody (6A6) (10 or 20 μg/mouse, i.p., a single dose at day 3) shows anti-tumor effect in WF-3/Luc tumor mice models[2].
Anti-Mouse BTLA/CD272 Antibody (6A6) (100 μg/mouse, i.p., twice per week for two weeks) consistently increases the frequency of both T follicular helper and T follicular regulatory cells within peyer’s patches in Btla or Tnfrsf14-deficient mice models[3].
Anti-Mouse BTLA/CD272 Antibody (6A6) (10 µg/g, i.p., a single dose) permanently prevents graft versus host disease (GVHD) in lethal mice model of GVHD[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice were grafted with allogeneic tail skin on the right flank (female, 8-12 weeks)[1]
-
Dosage:1 mg
-
Administration:Intraperitoneally injection
-
Result:Reduced B cells, follicular B cells and GC B cells.
Upregulated HVEM expression on follicular and extrafollicular allogeneic Th cells.
Enhanced HVEM expression in both draining (ongoing alloreactive response) and non-draining (resting non-inflammatory response) LNs.
-
Animal Model:C57BL/6 J mice were challenged with WF-3/Luc tumor cells[2]
-
Dosage:10 and 20 μg/mouse
-
Administration:Intraperitoneally injection, at day 3
-
Result:Suppressed tumor growth.
Displayed the highest survival rate combined with paclitaxel (Hy-B0015).
-
Animal Model:Btla or Tnfrsf14-deficient genetic models[3]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, twice per week for two weeks
-
Result:Consistently increased the frequency of both Tfh and Tfr cells within PPs.
-
Animal Model:Lethal model of graft versus host disease (GVHD) [4]
-
Dosage:10 µg/g
-
Administration:Intraperitoneally injection
-
Result:Eliminated weight loss, histological changes, and clinical signs of graft versus host disease.
Allowed for the expansion of preexisting donor-derived T reg cells by inhibiting T eff cell proliferation.
Increased frequency of CD4+ Foxp3+ cells.
Did not lead to global immunosuppression.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo BTLA stimulation; in vivo BTLA blockade
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse BTLA/CD272 Antibody (6A6)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Rodriguez-Barbosa JI, et al. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway. Cell Mol Immunol. 2017 Jun;14(6):497-510. doi: 10.1038/cmi.2015.101IF: 19.8 Q1 . Epub 2016 Feb 29. Erratum in: Cell Mol Immunol. 2019 Mar;16(3):314. [Content Brief]
[2]. Chen YL, et al. BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes. J Immunother Cancer. 2019 Nov 21;7(1):313. [Content Brief]
[3]. Stienne C, et al. Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa. Cell Rep. 2022 Mar 22;38(12):110553. [Content Brief]
[4]. Albring JC, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010 Nov 22;207(12):2551-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse BTLA/CD272 Antibody (6A6) Related Classifications
HY-P990298 Related Classifications
Powered by Bioz